Aktienanalyse zu Anixa Biosciences Inc (ANIX)ANIXAnixa Biosciences Inc

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Anixa Biosciences Inc is a good buy right now due to its current price of $2.99, which is significantly below its 52-week high of $5.46, indicating potential for price recovery. The RSI is at 46.686, suggesting the stock is neither overbought nor oversold, which is favorable for entry. Additionally, the company has a forward P/E ratio of 0, indicating no earnings expectations, but this could change as they advance their breast cancer vaccine into Phase 2 trials, which has shown promising results in Phase 1. The main risk is the negative net income, which has been consistently around -2.5 million USD in recent quarters, indicating ongoing financial challenges that investors should consider.

1 analysts cover ANIX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.